Polypill Therapy in Cardiovascular Disease: A Meta-Analysis of Randomized Controlled Trials

WHO media center. Cardiovascular diseases. Available at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) Accessed October 2, 2022. Roth, 2020, Global burden of cardiovascular diseases and risk factors, 1990–2019, J Am Coll Cardiol, 76, 2982, 10.1016/j.jacc.2020.11.010 Regmi, 2022, Prevention of coronary artery disease Wald, 2003, A strategy to reduce cardiovascular disease by more than 80%, BMJ, 326, 1419, 10.1136/bmj.326.7404.1419 Roy, 2017, Strengths and limitations of the use of the polypill in cardiovascular prevention, Curr Cardiol Rep, 19, 45, 10.1007/s11886-017-0853-y Lonn, 2010, The polypill in the prevention of cardiovascular diseases, AHA J, 122, 2078 Bayorh, 2005, Simvastatin and losartan improve nitric oxide and reduce oxidative stress in salt-induced hypertension, Am J Hypertens, 18, 1496, 10.1016/j.amjhyper.2005.05.022 Abdel-Zaher, 2014, Effect of simvastatin on the antihypertensive activity of losartan in hypertensive hypercholesterolemic animals and patients: role of nitric oxide, oxidative stress, and high-sensitivity C-reactive protein, Fundam Clin Pharmacol, 28, 237, 10.1111/fcp.12020 Munro, 1994, Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates in cholesterol synthesis, Eur J Clin Invest, 24, 766, 10.1111/j.1365-2362.1994.tb01074.x Yusuf, 2021, Polypill with or without aspirin in people without cardiovascular disease, N Engl J Med, 384, 216, 10.1056/NEJMoa2028220 Munoz, 2019, Polypill for the prevention of cardiovascular diseases in an underserved population, N Engl J Med, 381, 1114, 10.1056/NEJMoa1815359 Roshandel, 2019, Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (Polylran): a pragmatic, cluster-randomised trial, Lancet, 394, 672, 10.1016/S0140-6736(19)31791-X Soliman, 2011, A polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization, Trials, 12 Lafeber, 2016, Estimated reduction of cardiovascular relative risk from fixed-dose combination pill (polypill) treatment in a wide range of patients with moderate risk of cardiovascular disease, Eur J Prev Cardiol, 23, 1289, 10.1177/2047487315624523 Lafeber, 2017, Impact of switching from different treatment regimens to a fixed dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk, Eur J Prev Cardiol, 24, 951, 10.1177/2047487317695616 Patel, 2015, A pragmatic randomized trial of a polypill-based strategy to improve the use of indicated preventive treatments in people at high risk for cardiovascular disease, Eur J Prev Cardiol, 22, 920, 10.1177/2047487314530382 Malekzadeh, 2010, A pilot double-blind, placebo-controlled trial of the effects of fixed-dose combination therapy (polypill) on cardiovascular risk factors, Int J Clin Pract, 64, 1220, 10.1111/j.1742-1241.2010.02412.x Oh, 2018, Clin Ther, 40, 676, 10.1016/j.clinthera.2018.03.010 Park, 2016, Drug Des Devel Ther, 10, 2599, 10.2147/DDDT.S112873 Kl, 2019, Efficacy and safety of a fixed-dose combination of candesartan and rosuvastatin on blood pressure and cholesterol in patients with hypertension and hypercholesterolemia: a multicenter, randomised, double blind, parallel phase III clinical study, Clin Ther, 41, 1508, 10.1016/j.clinthera.2019.05.007 Thom, 2013, Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial, JAMA, 310, 918, 10.1001/jama.2013.277064 Hong, 2019, Efficacy and safety of triple therapy with telmisartan, amlodipine, and rosuvastatin in patients with dyslipidemia and hypertension: the jeil telmisartan, amlodipine, and rosuvastatin randomized clinical trial, Clin Ther, 41, 233, 10.1016/j.clinthera.2018.12.008 Selak, 2014, Effect of fixed-dose combination treatment on adherence and risk factor control among patients at high risk for cardiovascular disease: a randomised controlled trial in primary care, BMJ, 348, g3318, 10.1136/bmj.g3318 Kim, 2016, Blood pressure and cholesterol-lowering efficacy of a fixed-dose combination with irbesartan and atorvastatin in patients with hypertension and hypercholesterolemia: a randomized, double-blind, factorial, multicenter phase III study, Clin Ther, 38, 2171, 10.1016/j.clinthera.2016.09.005 Kim, 2020, A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension, J Clin Hypertens (Greenwich), 22, 261, 10.1111/jch.13774 Grimm, 2010, Simultaneous treatment to achieve blood pressure and lipid goals and reduced CV risk burden using single-pill amlodipine /atorvastatin therapy in treated hypertensive participants in a randomized controlled trial, Vascular Health and Risk Management, 6, 261, 10.2147/VHRM.S7710 Ros-Castelló, 2020, Use of the cardiovascular polypill in secondary prevention of cerebrovascular disease: a study of a cohort of tertiary hospitals in real life of 104 patients, Cerebrovasc Dis Extra, 10, 166, 10.1159/000511064 Albaladejo, 2010, Patients under antiplatelet therapy, Best Practice Res Clin Anaesthesiol, 24, 41, 10.1016/j.bpa.2009.09.008 Navaratnam, 2017, How important is adherence to aspirin when evaluating the efficacy of low-dose aspirin?, Eur J Obstet Gynecol Reprod Biol, 219, 1, 10.1016/j.ejogrb.2017.10.004 Bahiru, 2017, Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases, Cochrane Database Syst Rev, 3 de Cates, 2014, Fixed-dose combination therapy for the prevention of cardiovascular disease, Cochrane Database Syst Rev, 16, 10.1002/14651858.CD009868.pub2 Segar, 2021, Development and validation of optimal phenomapping methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes, Diabetologia, 64, 10.1007/s00125-021-05426-2 Cholesterol Treatment Trialists, 2012, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease:meta-analysis of individual data from 27 randomised trials, Lancet, 380, 581, 10.1016/S0140-6736(12)60367-5 Rose, 1985, Sick individuals and sick populations, Int J Epidemiol, 14, 32, 10.1093/ije/14.1.32 Lonn, 2010, The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions, Circulation, 122, 2078, 10.1161/CIRCULATIONAHA.109.873232 Lee, 2018, Relationships among medication adherence, lifestyle modification, and health-related quality of life in patients with acute myocardial infarction: a cross-sectional study, Health Qual Life Outcomes, 16, 100, 10.1186/s12955-018-0921-z Elley, 2012, The efficacy and tolerability of “polypills”: metaanalysis of randomised controlled trials, PLoS One, 7, e52145, 10.1371/journal.pone.0052145 Kolandaivelu, 2014, Non-adherence to cardiovascular medications, Eur Heart J, 35, 3267, 10.1093/eurheartj/ehu364 Santo, 2016, Interventions to improve medication adherence in coronary disease patients: a systematic review and meta-analysis of randomized controlled trials, Eur J Prev Cardiol, 23, 1065, 10.1177/2047487316638501 Thakkar, 2016, Mobile telephone text messaging for medication adherence in chronic disease: a meta-analysis, JAMA Intern Med, 176, 340, 10.1001/jamainternmed.2015.7667 Rao, 2022, Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: a systematic review and meta-analysis of randomized controlled trials, Prog Cardiovasc Dis, 73, 48, 10.1016/j.pcad.2022.01.005